Saliva Diagnostics (SALV) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Saliva Diagnostics (SALV)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Keiko who wrote (2115)	2/18/1998 1:48:00 AM
From: rl	Read Replies (1) of 3369

Thanks for this enlightening info. With all the argument and scapegoating that's going on, I found this report quite interesting in terms of the current SALV CEO. A quote from Bruce today "He (McLachlan) agrees with me that the big market is in professional sales, not over the counter." Now you have directed us to one of the most highly regarded analysts in the field, Frost and Sullivan, who write "...the potential benefits of point of care tests are undeniable and could one day ALL BUT ELIMINATE THE CURRENT CLINICAL LABORATORY SYSTEM." This means that over the counter testing "will expand significantly in the near future" covering more than the current 25% of the diagnostic market. The advantages and potential for the SALV products is what excites me and always has. Neither Trinity nor anyone else can match this technology. To have a CEO that does not understand this basic concept is the root of the problem, especially if he is absentee. How can it not be obvious that there is a bigger market for an HIV test at the pharmacy than anywhere else? That alone displays an almost ridiculous lack of understanding for what SALV stands for and is its' only value.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next